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Real-time reverse transcriptase–polymerase chain reaction (RT–PCR) is a technique with the potential of improving the
quantification of disseminated epithelial cells (DEC) in haematological tissues due to its exquisite sensitivity. This sensitivity may lead
to false positivity. Immunocytochemistry (ICC) is regarded as the standard methodology to diagnose DEC. In this study, detection
with ICC was compared with quantitative real-time RT–PCR for CK-19 and mammaglobin (hMAM) mRNA in bone marrow (BM) of
patients with metastatic breast cancer (MBC). Bone marrow was aspirated from 14 control patients and from 29 patients with MBC.
Mononuclear cells (MNC) were isolated. Immunostaining was carried out with the Epimet kit. Quantitative PCR was performed on
the ABI Prism 7700. The CK-19 and hMAM mRNA quantities were normalised against b-Actin and calculated relative to a calibrator
sample (relative gene expression). All controls were negative by ICC and for hMAM expression measured by RT–PCR, whereas the
median RGE value for CK-19 was 0.57. For the MBC patients, the median RGE for hMAM was 0 and 10 out of 25 (40%) tested
positive. Median RGE for CK-19 was 2.9 and 20 out of 25 (80%) tested positive. With ICC, the median value was 1 stained cell per
sample, and 15 out of 24 (62%) samples were positive. A correlation was observed between CK-19 and hMAM expression (r¼0.7;
P¼0.0003), and between hMAM expression and ICC (r¼0.6; P¼0.003). CK-19 expression and ICC (r¼0.9; Po0.0001) showed
the strongest correlation. Reverse transcriptase–polymerase chain reaction for CK-19 resulted in a higher number of positive BM
samples of patients with MBC than ICC. Since an excellent correlation is observed between ICC and RT–PCR, and RT–PCR is
probably more sensitive with the advantage of being less observer dependent and thus also more easy to automate, we consider our
quantitative real-time RT–PCR method as validated for the detection of DEC in the bone marrow of breast cancer patients.
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In the Western world, nearly one out of nine women develop breast
cancer. The majority of these patients do not have evidence of
metastatic disease using conventional diagnostic techniques. How-
ever, almost 30% of patients with stage I or stage II disease will die of
metastasis, probably implying that dissemination, although unde-
tectable, had already occurred at the moment of diagnosis.
Detection of disseminated epithelial cells (DEC) in the blood–
bone marrow (BM) compartment is still in the experimental phase.
Molecular diagnostic techniques have, however, been integrated in
the revised tumour-node-metastasis (TNM) staging system for the
detection of metastatic tumour deposits in lymph nodes of patients
with breast cancer (Singletary et al, 2002).
The standard method to detect DEC in BM is immunocyto-
chemistry (ICC). For patients with breast cancer, several studies
demonstrated that the presence of ICC-stained cytokeratin-
positive cells in the bone marrow is associated with a poor
prognosis (Diel et al, 1996; Braun et al, 2000; Janni et al, 2000;
Gerber et al, 2001; Singletary et al, 2002; Wiedswang et al, 2003).
The value of this cytological method is limited by its low
sensitivity, and is highly dependent on the experience of the
observer. An additional well-known problem is the false positivity
of some haematological cells (Borgen et al, 1999).
Since the introduction of molecular-based techniques,
more sensitive quantitative methods have been developed, for
instance, based on PCR methodology. This approach is aimed
at the amplification of specific abnormalities present in the
DNA of tumour cells. Since the common solid tumours rarely have
specific genetic abnormalities, the use of DNA-based methods is
precluded. The most commonly used molecular method for
the detection of DEC relies on the screening for tumour-associated
and/or organ-specific mRNA expression in cancer cells and on
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tissue such as BM.
The identification of an appropriate target gene is one of the
most critical steps in the reverse transcriptase–polymerase chain
reaction (RT–PCR) approach to quantify DEC. Cytokeratins are
widely evaluated as targets for the detection of DEC, but many
studies have reported on the problem of false positivity, for
example, with the detection of CK-19 mRNA, which may be
explained by illegitimate expression by nonepithelial cells (Chelly
et al, 1989; Ko et al, 2000). Combining markers may increase both
the specificity and the sensitivity of the detection of DEC. Human
mammaglobin (hMAM), a member of the uteroglobin gene family,
was reported to be exclusively expressed in mammary epithelium
(Watson and Fleming, 1996; Watson et al, 1999), making it a
potentially useful RT–PCR target.
A prerequisite for the prognostic/predictive evaluation of DEC
in the BM quantified by RT–PCR, and the aim of this study, is the
proof of a stochastic correlation of the molecular quantitative
method with ICC-based quantification of DEC. Some studies
(Schoenfeld et al, 1997; Zhong et al, 1999) have adopted the
molecular approach, but not in a quantitative manner, having
expressed the BM as being DEC-positive or negative. Slade
(1999) and Smith et al (2000) use a competitive quantitative
RT–PCR assay and compare the results with ICC. In this
study, quantification of BM DEC by ICC is compared with
quantitative real-time RT–PCR quantification of CK-19 and
hMAM mRNA expression in a control population and in
patients with metastatic breast cancer.
PATIENTS AND METHODS
Patient samples
After written informed consent, BM aspirates were taken from 29
patients with metastatic breast cancer and 14 patients with a
nonmalignant breast lesion or a haematological malignancy
(control patients).
In total, 18ml of BM was aspirated from the posterior iliac crest
under local anaesthesia into syringes containing heparin as
anticoagulant.
Mononuclear cells (MNC) were isolated by density-gradient
centrifugation through Ficoll-Paque (Amersham Pharmacia Bio-
tech, Sweden) and washed twice with PBS. The samples were then
divided into two aliquots, one for each methodology. After
centrifugation, the cell pellets were resuspended in a guanidine-
containing buffer or in PBS, for RT–PCR and ICC, respectively.
For optimalisation of the assay, BM aspirates were also analysed
from 56 consecutive patients with operable breast cancer presented
in our hospital.
The study protocol was approved by the ethical committees of
the Faculty of Medicine, University of Antwerp, and of the General
Hospital Sint-Augustinus.
Immunocytochemistry
The MNC suspension was counted and cytocentrifuged onto glass
slides at a concentration of 5 10
5 cells per spot. The cytospin
preparations were air-dried overnight and then stored at  801C.
Immunostaining to detect cytokeratin-positive cells was carried
out with the Epimet
s-kit (Micromet AG, Germany). This kit uses
the monoclonal antibody A45-B/B3, a pancytokeratin marker. A
total of 2 million cells per patient were screened microscopically
by two independent observers. Cells were identified as DEC
according to the European ISHAGE Working group for Standar-
disation of Tumour Cell Detection (Borgen et al, 1999). Results
were expressed as the number of positive cells per million
MNC (continuous data). A sample was considered to be positive
if one or more stained cells were observed in the cytospins
(categorical data).
Sensitivity was tested on an MNC suspension from a healthy
volunteer spiked with 1, 2, 10, 20, 100 and 1000 MCF-7 breast
cancer cells per million MNC.
RNA isolation and cDNA synthesis
Total RNA was extracted from the MNC using the RNeasy kit
(Qiagen, Germany). The amount of RNA was measured spectro-
photometrically. All samples had an OD 260/280nm ratio 41.8,
indicating high purity. The RNA integrity was tested on the Agilent
Bioanalyzer. Only samples with lack of degradation on electro-
pherogram and 28S/18S ratio were analysed.
For the generation of first strand cDNA, 2mg of total RNA was
reverse transcribed with the high-capacity cDNA Archive Kit
(Applied Biosystems, The Netherlands) in a total volume of 100ml.
PCR amplification
cDNA-specific CK-19 and hMAM Taqmant primer and probe sets
were developed using Primer Express
s software. To avoid
amplification of contaminating genomic DNA, primers and probes
were placed on different exons. The forward primer of CK-19
(CCCGCGACTACAGCCACTA) is situated on exon 1, the probe
(FAM-ACCATTGAGAACTCCAGGATTGTCCTGCA-TAMRA) on
exon 2 and the reverse primer (CTCATGCGCAGAGCCTGTT) on
exon 3. Reverse transcriptase–polymerase chain reaction using
this primer set resulted in a 163bp fragment.
For hMAM, the forward primer (ATGAAGTTGCTGATGGTCCT
CAT) and the probe (FAM-CGGCCCTCTCCCAGCACTGC-TAM
RA) are located on exon 1 and the reverse primer (GTCTTAGA
CACTTGTGGATTGATTGTCT) on exon 2. The hMAM amplicon
consists of 119bp. The nucleotide sequences of the primers and
probes were checked for their specificity in the NCBI BLAST
s
database.
A ready to use primer and probe set predesigned by Applied
Biosystems (Assay-on demand Gene Expression Product number
Hs00267190_m1, SCGB2A2) was also used for the detection of
hMAM expression. Commercially available primers and probes for
GAPDH and b-Actin mRNA were used for normalisation (Applied
Biosystems). These probes are labelled with a VIC dye and to avoid
competition in the multiplex PCR reaction tube, the concentra-
tions of the primers are limited.
All PCR reactions were performed on the ABI Prism 7700
Sequence Detection System (Applied Biosystems) using the
fluorescent Taqman methodology. The PCR cycle at which the
fluorescence arises above the background signal is called the cycle
threshold (Ct).
In total, 10ml of the reverse transcription volume was used for
each PCR reaction in a total volume of 50ml. Since a multiplex PCR
reaction is carried out, each reaction tube contains more than one
primer pair: one primer pair amplifies the target and another pair
amplifies the endogenous reference. Primer and probe concentra-
tion for the target gene were optimised according to the
manufacturer’s procedure. For CK-19 mRNA, the concentrations
were 300nM for forward and reverse primers and 150nM for the
probe. The forward and reverse primers for hMAM mRNA
detection were used in a concentration of 900nM and the probe
in a concentration of 200nM. The primers and probe of the
predeveloped assay-on-demand were used according to the
manufacturer’s guidelines. The thermal cycling conditions com-
prised 2min at 501C, 10min at 951C and 50 cycles of 15s
denaturation at 951C and 60s annealing at 601C.
The CK-19 and hMAM mRNA quantities were analysed in
triplicate, normalised against b-Actin or GAPDH as a control gene
and expressed in relation to a calibrator sample. As described by
Livak and Schmittgen (2001), results are expressed as relative gene
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yexpression (RGE) using the DD Ct method. The calibrator was
produced from the blood of a healthy volunteer spiked with 5
MDA-MB361 cells per 10
6 MNC. The calibrator was given a RGE
value of 100.
Cell lines
The cell lines were cultured in Dulbecco’s MEM culture medium
(MCF-7 and MDA-MB231) and in Leibovitz medium for MDA-
MB361. The media contained 10–20% fetal bovine serum and
antibiotics. MCF-7 and MDA-MB231 cells were cultured at 371Ci n
a5 %C O 2 atmosphere. The medium was replaced twice a week.
MDA-MB361 cells were cultured in the normal atmosphere and the
medium was replaced only once a week. Culture cells were
harvested according to the American Type Culture Collection
(ATCC) guidelines.
For total RNA isolation, cells were pelleted and washed twice
with PBS. Pellets were resuspended in RLT buffer (Qiagen), and
RNA was prepared according to the Rneasy midi protocol.
Standard curves
A standard curve was constructed with a six-fold serial dilution of
cDNA obtained from an MDA-MB361 breast cancer cell line. The
standard curve was composed of six points with an equivalent of
200, 100, 40 and 20, 2 and 0.2ng MDA-MB361 total RNA. This
standard curve was presented as an XY scatter plot, where the
X-axis represents the log of the input amount (log pg of starting
total RNA) and the Y-axis the corresponding Ct value. Equations
were derived from the curves.
Sensitivity of CK-19 and hMAM RT–PCR was tested on limiting
dilutions of a BM aspirate spiked with MDA-MB361 cells to obtain
the following concentrations: 0, 0.5, 1, 2, 5, 10, 50, 100, 1000 and
10000 cells per 10
6 MNC.
Statistics
Data were analysed using the statistical software package SPSS
11.0. The Mann–Whitney U-test was used to validate differences in
continuous variables and the Fisher’s exact test was used to
validate differences in categorical variables. Correlation analyses
were validated by the Spearman r correlation test for continuous
non parametric variables and by the k test for categorical variables.
The McNemar test was used to compare ICC and RT–PCR on the
same BM sample.
RESULTS
Immunocytochemistry
By screening 2 million MNC of the healthy volunteer’s blood
spiked with breast cancer cells, a sensitivity of 10 tumour cells per
million MNC was obtained.
In none of the 14 BM aspirates from negative control patients
were cytokeratin- positive cells detectable. Cytokeratin-positive
cells were counted in cytospins from 24 metastatic breast cancer
patients (five patients were excluded for ICC analysis because of
insufficient sample collection or poor cytospin quality). The
median number of positive cells in these patient samples was one
cell10
6MNC
 1 (minimum 0 and maximum 122). In 62% (15 out of
24) of the patients, at least one cell was immunostained.
CK-19 and hMAM expression in various breast cancer cell
lines
CK-19 and hMAM expressions were measured in MCF-7, MDA-
MB231 and MDA-MB-361 breast cancer cell lines. CK-19 mRNA
could be amplified in all three cell lines with the strongest
expression in the MCF-7 cell line (Ct of 15.39, vs 19.50 and 18.36 in
MDA-MB231 and MDA-MB361, respectively). Mammaglobin
mRNA expression was not detectable in the cell line MDA-
MB231. A very weak expression was found in the MCF-7 cell line
(Ct of 39.07). MDA-MB361 cells had a strong hMAM expression
(Ct of 14.58).
Sensitivity of quantitative RT–PCR for CK-19 and hMAM
mRNA
Five MDA-MB361 cells in a total of 10 million MNC were still
detectable with the CK-19 RT–PCR test. Human mammaglobin
RT–PCR was positive up to two MDA-MB361 cells per million MNC.
Normalisation to housekeeping genes
For exact quantification of gene expression, an active and
endogenous reference (housekeeping gene) is used to correct for
differences in the amount of total RNA added to a reaction, for
compensation of different RT efficiencies and for compensation of
PCR inhibitors in the sample.
We evaluated the two most frequently used housekeeping genes
for normalisation of our results: GAPDH and b-Actin. Primers and
probes for these housekeeping genes were commercially available
and according to the manufacturer, these assay reagents were
designed to exclude detection of genomic DNA. These assays did
not detect the genomic DNA after 35 cycles of amplification.
The expression of these two markers was measured in 81 BM
samples from patients with breast cancer (25 patients with
metastatic disease, 56 with operable disease). Coefficients of
variation were measured according to the difference in the Ct
value (Figure 1, Table 1). Since the BM aspirates showed a wide
variation in GAPDH expression (CV 12%), while b-Actin was
expressed more stably (CV¼3.8%), b-Actin was selected as the
endogenous control.
Box and Whiskers graph
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Figure 1 Representation of the variation in Ct value for GAPDH and
b-Actin measured in 81 bone marrow samples.
Table 1 Variation of GAPDH and b-Actin expression in BM samples
GAPDH b-Actin
N 81 81
Mean Ct 17.05 15.46
s.d. 2.1 0.6
CV 12% 3.80%
N¼number of samples analysed; Ct¼cycle threshold; s.d.¼standard deviation;
CV¼coefficient of variation; GAPDH¼glyceraldehyde 3 phosphate dehydrogenase.
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We used the DD Ct method to quantify our results. To adopt this
calculation method, the amplification efficiencies of the target gene
(CK-19 or hMAM) and endogenous control gene (GAPDH or
b-Actin) have to be comparable: the slope of the plot of the log of
input of total RNA vs the DCt value has to be p0.1. For CK-19 vs
GAPDH, a slope of 0.08 was found. For CK-19 vs b-Actin, a slope of
0.1 was found. The amplification efficiencies of hMAM and
GAPDH or b-Actin were also equal (slopes of 0.08 and 0.01,
respectively) (Figure 2).
Comparison of a manufacturer-designed primer and probe
set and a home-made primer and probe set for the
detection of hMAM mRNA
Primers and probe sequences from the Assay-on-demand (Applied
Biosystems) are not revealed by the manufacturer. Only sequence
context information, consisting of 25 bases randomly selected
around the probe, is available. In Figure 3, the hMAM mRNA
sequence is given. The 25 bases are highlighted as are the primers
and probe sequences constructed in the laboratory.
In total, 30 BM samples – six negative control patients (NC), 13
MBC patients and 11 patients with operable breast cancer (PBC) –
were tested with both primer and probe sets for the quantification
(RGE) of hMAM mRNA. Results are given in Table 2. A strong and
highly significant concordance was found between the two primer/
probe sets (N¼30, Spearman r¼0.9985, Po0.0001).
Reverse transcriptase–polymerase chain reaction
Only in 11 out of 14 specimens from the control samples, and 25
out of 29 specimens from patients with MBC, RNA of good quality
was isolated. These samples were used for further analysis.
In none of the 11 negative control samples, was hMAM
expression measurable by RT–PCR. On the other hand, CK-19
mRNA could be quantified in all control samples, with a median
RGE of 0.57 (range 0.22–0.78) (Table 3). Taking the 95 percentile
from the CK-19 RGE (0.77) of the negative control group as cutoff,
20 of the 25 (80%) BM aspirates from the MBC patients had an
increased CK-19 expression. The RGE of CK-19 of this patient
group, ranged between 0.25 and 82409 (med 2.9) and the RGE of
hMAM between 0 and 262.7 (med 0). In 10 of the 25 (40%)
samples, hMAM expression was measurable.
With the exception of one sample, all patients with detectable
hMAM mRNA also had an increased CK-19 expression.
A statistically significant difference was observed between the
RGE of CK-19 of control patients and MBC patients (Mann–
Whitney: P¼0.005). The RGE of hMAM was 40 in 10 out of 25
MBC patients (Fisher’s exact test: P¼0.016).
Correlation RT–PCR and ICC
A strong correlation was found between CK-19 and hMAM RGE in
the BM (N¼25, Spearman r¼0.7, P¼0.003, CI¼0.2–0.8). In 20
of the 29 patients with MBC, results for detection of DEC were
obtained by the two techniques: ICC and PCR. A strong correlation
between ICC detection of CK-positive cells and CK-19 RGE
(N¼20, Spearman r¼0.9, Po0.0001, CI 0.8–1) or hMAM RGE
(N¼20, Spearman r¼0.6, P¼0.003, CI 0.2–0.8) was observed.
In 25% (five out of 20) of the patient samples with a CK-19 RGE
above the cutoff, no cytokeratin-positive cells were detected. On
the other hand, there was no sample that had a positive ICC result
and an RGE of CK-19 below the cutoff (concordance: 75%, Mc
Nemar: P¼0.06 ‘fair’ k value of 0.42). (Table 4). For hMAM
expression, a concordance with ICC of 70% is found (Mc Nemar:
P¼0.22), with a fair k value as well (0.42).
DISCUSSION
Current guidelines for the adjuvant treatment of patients with
lymph node negative breast cancer result in overtreatment, with
inherent disadvantages and even health risks. In conjunction with
increasingly effective adjuvant strategies, a more optimal patient
selection is thus a matter of critical importance. Genomic
expression profiling is one potential modality of obtaining a
powerful predictor for patients with localised breast cancer (Van
de Vijver et al, 2002; Van’t Veer et al, 2002). The presence and the
number of DEC in patients with breast cancer at diagnosis may be
a marker for early metastasis. Numerous studies spanning a period
of more than 30 years and a recent pooled analysis have
corroborated the prognostic impact of the presence of the so-
called ‘BM micrometastasis’ (Braun et al, 2003). The studies are all
based on the morphological detection of epithelial cells in BM as
demonstrated by specific immunostaining.
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Figure 2 Validation of the DD Ct method for the quantification of
hMAM results: (A) amplification plots obtained by the ABI Prism 7700 for
hMAM mRNA expression; (B) Standard curve for hMAM and b-Actin
constructed of six cDNA dilutions obtained from an MDA-MB361 breast
cancer cell line; (C) Plot of the log of input of total RNA vs the DCt value
(Ct hMAM - Ct b-Actin).
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cell detection. This observer-dependent method is hampered by a
low sensitivity and is labour intensive. False-positive staining of
haematological cells (Borgen et al, 1999) can occur. With the
Epimet
s staining kit, we observed no doubtful cells in BM of our
control population.
Molecular diagnostics have, in this respect, the advantage of
being both sensitive and easy to integrate in laboratory practice,
but the lack of morphological proof of a signal necessitates
validation experiments. Reverse transcriptase–polymerase chain
reaction assays are more suitable for routine laboratory analysis.
Some RT–PCR assays have been developed to improve the
sensitivity of the detection of DEC in BM (Ghossein and Rosai,
1998; Ghossein et al, 1999; Lambrechts et al, 1999; Slade et al, 1999;
Zach et al, 1999; Zhong et al, 1999; Berois et al, 2000; Hu and
Chow, 2000; Zippelius and Pantel, 2000; Corradini et al, 2001).
The optimal approach for the RT–PCR-based quantification of
DEC in breast cancer would be the amplification of breast cancer
cell-specific mRNA transcripts. The alternative is to exploit
epithelial cell-specific gene expression. Amplification of CK-19
mRNA is used in many studies, and false positivity due to
illegitimate expression by nonepithelial cells is reported (Chelly
et al, 1989; Ko et al, 2000). In the present study, CK-19 mRNA
transcripts were detectable in all BM samples of the control
patients. Owing to this, a quantitative interpretation was adopted,
introducing a cutoff threshold above which a sample was
considered positive (the 95th percentile of the RGE for CK-19 of
the control patients). The final aim is to select patients who do not
need adjuvant chemotherapy, but with minimal risk of failing to
identify those patients with very low levels of DEC. False-negative
RT–PCR results thus have to be avoided. For this reason, a more
stringent cutoff was not considered appropriate.
gacagcggcttccttgatccttgccacccgcgactgaacaccgacagcagcagcctcaccatgaagttgctgatggtcctcatgctggcggccctctcccagcactgc
tacgcag//gctctggctgccccttattggagaatgtgatttccaagacaatcaatccacaagtgtctaagactgaatacaaagaacttcttcaagagttcatagacgac
aatgccactacaaatgccatagatgaattgaaggaatgttttcttaaccaaacggatgaaactctgagcaatgttgaggtgtttatg//caattaatatatgacagcagtc
tttgtgatttattttaactttctgcaagacctttggctcacagaactgcagggtatggtgagaaaccaactacggattgctgcaaaccacaccttctctttcttatgtctttttactacaa
actacaagacaattgttgaaacctgctatacatgtttattttaataaattgatggca 
Figure 3 Human mammaglobin mRNA sequence: //indicates exon–intron boundary, ¼our own primers and probe, ¼neighbourhood of probe
location of the assay-on-demand.
Table 2 Human mammaglobin expression measured in 30 different
bone marrow samples with two different primers and probe sets
Patient number Group RGE hMAM RGE hMAM AOD
1 MBC 0.2 0.06
2 PBC 0 0
3 PBC 0.78 0.60
4M B C 00
5M B C 00
6N C 00
7 PBC 0 0
8 MBC 262.68 86.06
9N C 00
10 MBC 27.29 9.1
11 NC 0 0
12 PBC 0 0
13 MBC 0.77 0.07
14 PBC 0 0
15 PBC 0 0
16 PBC 0 0
17 MBC 0 0
18 MBC 133.48 72.70
19 NC 0 0
20 NC 0 0
21 PBC 0 0
22 MBC 0 0
23 NC 0 0
24 PBC 0 0
25 PBC 0 0
26 MBC 1.54 0.43
27 MBC 0.34 0.07
28 PBC 0 0
29 MBC 162.45 137.55
30 MBC 0 0
RGE¼relative gene expression; AOD¼assay on demand; MBC¼metastatic breast
cancer patient; PBC¼primary breast cancer patient; NC¼ negative control patient.
Table 3 Detection of disseminated epithelial cells by ICC and RT-PCR in
bone marrow aspirates from control patients and patients with metastatic
breast cancer
Control patients MBC patients
ICC (#/10
6)
N 14 24
Median 0 1
Minimum 0 0
Maximum 0 2280
No. of pt 4cutoff 0 15/24
RGE CK-19
N 11 25
Median 0.57 2.9
Minimum 0.22 0.25
Maximum 0.78 82409
No. of pt 4cutoff 1 20/25
RGE hMAM
N 11 25
Median 0 0
Minimum 0 0
Maximum 0 262.7
No of pt 4cutoff 0 10/25
MBC¼metastatic breast cancer; ICC¼immunocytochemistry; RGE¼relative gene
expression; hMAM¼human mamaglobin; RT-PCR¼reverse transcriptase-polymer-
ase chain reaction.
Table 4 Comparison between ICC and CK-19 RT-PCR for the
detection of disseminated epithelial cells in bone marrow aspirates
Number of patients ICC¼0I C C 40
RGE CK-19 40.77 5 12
RGE CK-19 o0.77 3 0
RGE hMAM 401 7
RGE hMAM¼07 5
ICC¼immunocytochemistry; RT-PCR¼reverse transcriptase–polymerase chain
reaction; RGE¼relative gene expression; hMAM¼human mammaglobin.
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samples might lead both to false-negative and false-positive
analyses. Reverse transcriptase–polymerase chain reaction accord-
ing to the Taqman methodology was performed to quantify DEC in
leukapheresis products of breast cancer patients by the RGE using
a panel of genes related to the breast gland or involved in breast
cancer: maspin, mammaglobin and c-ErbB-2 (Leone et al, 2001).
Maspin and mammaglobin were not expressed in control samples,
and the mammaglobin expression was the most sensitive single
marker to detect DEC. An additional reason for false negativity is
the inherent mutator phenotype of cancer resulting in hetero-
geneous gene expression patterns, both topographically and
temporally, within a tumour. Gene expression patterns of different
DEC of a patient with breast cancer probably show the same
heterogeneity (Klein et al, 2002; Schmidt-Kittler et al, 2003). Gene
expression most probably is also context dependent, with other
genes being expressed as dictated by different extracellular
components in different end organs.
Mammaglobin expression was used as a second marker to
quantify DEC in the BM of patients with breast cancer. The
specificity of this marker for the detection of breast cancer cells in
haematopoietic products has been evaluated in several studies, but,
with the exception of one study (Suchy et al), without additional
quantitative analysis (Leygue et al, 1999; Zach et al, 1999; Suchy
et al, 2000; Corradini et al, 2001; Silva et al, 2002; Lin et al, 2003).
In our study population, 80% of the patients with metastatic
breast cancer had an elevated CK-19 expression in their BM
aspirates. Only in 40% of these patients with metastatic breast
cancer was hMAM mRNA amplificable.
To check for the specificity of our home-designed primer and
probe combination, we compared it with a predesigned ready to
use primer and probe set prepared by Applied Biosystems (Assay-
on demand Gene Expression Product number Hs00267190_m1).
Primers and probe for this assay are designed using all available
public and private genome databases. In order to design a robust
assay for hMAM transcript detection, SNPs, repeats, sequence
discrepancies and penalised regions of high homology are masked.
All the components are quality controlled tested and functionally
tested on human cDNA. No discrepancies were observed when
RGE was measured with our home-made primers/probe set and
compared with the predeveloped set (Figure 2). All samples with
no hMAM expression in our designed assay also had no
mammaglobin amplification with the predeveloped assay.
Also the variability in mammaglobin expression in different
breast (cancer) tissues may explain the variability in expression.
Leone et al (2001) found a high intertumoral variability of
mammaglobin expression levels. Zach et al (1999) confirmed that
different breast cancer cell lines show different mammaglobin
expression levels. A similar variable expression between different
cell lines was observed during our studies with no hMAM
expression in MDA-MB 231 cells, weak expression in MCF-7 cells
and strong expression in MDA-MB361 cells.
The group of Nunez-Villar (Nunez-Villar et al, 2003) suggested
that breast cancer specimens with an elevated hMAM expression
are better differentiated, have a lower proliferation rate and an
increased hormone dependence. They observed a significant
inverse correlation between a high mammaglobin expression and
the most important negative clinical prognostic factor for breast
cancer being axillary nodal involvement.
Suchy et al (2000) remarked that mammaglobin-expressing cells
in BM may define a specific subclass of tumour cell phenotypes.
Overexpression of mammaglobin may be restricted to a subset of
tumour cells. Detection of hMAM expression in BM aspirates is
restricted to cancer patients, therefore indicating absolute tumour
specificity. On the other hand, absence of hMAM expression does
not exclude the presence of tumour cells. Probably the presence of
a positive CK-19 signal and a positive hMAM expression will be
more specific for the presence of DEC. Grunewald et al (2000)
observed that hMAM expression is a superior marker for the
detection of breast cancer cells in peripheral blood as compared
with cytokeratin-19. The nested RT–PCR assay was not able to
measure mRNA levels quantitatively and thus resulted in false-
positive results for CK-19 expression. Therefore, only hMAM
mRNA expression correlated with clinical parameters. We will use
both mRNA markers (CK-19 and hMAM) in larger clinical studies
to evaluate this usefulness in the detection of DEC and to correlate
them with clinico pathological parameters. To quantify mRNA
expression in a sample, it is essential to correct for differences in
the amount of total RNA added to a reaction, to compensate for
different RT efficiencies, to compensate for PCR inhibitors in the
sample and for possible RNA degradation occurring during sample
processing. Therefore, an endogenous reference is used. Different
articles describe the difficulties in choosing a suitable house-
keeping gene (Kreuzer et al, 1999; Thellin et al, 1999; Bustin, 2000;
Vandesompele et al, 2002). Two of the most used housekeeping
genes for the detection of DEC in BM aspirates are GAPDH and
b-Actin. We measured the expression of both these markers in 81
different BM samples. Since the BM aspirates show a wide
variation in GAPDH expression while b-Actin is expressed equally
between the different samples, b-Actin was chosen as house-
keeping gene. Results of Re ´villion et al (2000) showed that GAPDH
expression is associated with breast cancer cell proliferation and
with the aggressiveness of tumours and therefore should not be
used as a control RNA.
We used the comparative Ct method, as previously described by
Livak and Schmittgen (2001), to quantify the relative gene
expression with the formula 2
 DDCt. This formula is based on
the assumption that the amplification efficiencies of the endogen-
ous reference and target gene (CK19 or hMAM) are approximately
equal and that the amplification efficiency is close to 1. This
assumption was tested by plotting the log of input of total RNA vs
the DCt value: the slope should be p0.1. For CK-19 vs GAPDH, a
slope of 0.08 was found and vs b-Actin 0.1. The amplification
efficiencies of hMAM and GAPDH or b-Actin were also equal
(sloop of 0.08 and 0.01). We decided that due to this validation,
experiment, the comparative Ct method might be used to quantify
our results relatively.
Despite the strong correlation found between quantitative ICC
results and quantitative RT–PCR results, expression of RT–PCR
as a number of positive cells remains difficult. Since the results
are expressed relatively to a calibrator sample, it may be possible
to recalculate RGE levels. For example, the maximum detectable
CK-19 RGE was 82409. This means that this sample has an
824 times higher CK-19 expression of mRNA than the calibrator
sample or an expression equal to 4120 MDA-MB361 cells per
million MNC.
We did not convert the RGE to number of tumour cells because
we argued that the expression level of CK-19 might vary
extensively between individual patients and between different
tumour cells. The amount of copies in tumour cells disseminated
in the BM of breast cancer patients might not only depend on the
number of tumour cells but also on the extent of CK-19 or hMAM
mRNA expression per single cell. It is impossible to distinguish
between one cell containing 10 copies of CK-19 mRNA and 10 cells
each containing one copy of CK-19 mRNA. Similarly, the
expression level of CK-19/hMAM of circulating tumour cells in
patients is not necessarily comparable with the expression level of
the cell line used to construct a standard curve, particularly since
cell lines are probably clonal with regard to target transcript copy
number. It remains possible that the variation in the expression
level of CK-19 mRNA in tumour cells between individual patients
is overruled by the variation in the number of circulating tumour
cells between these patients and that this assumption will explain
the correlation found between ICC and RT–PCR results.
Yet, quantitative RT–PCR is useful for at least two reasons: (1)
to establish a cutoff level to exclude false positivity and (2)
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prognostic information contained in the RGE.
In all, 12 out of 20 BM aspirates were positive by CK-19 RT–
PCR and ICC, whereas five out of 20 samples were positive by RT–
PCR but negative by ICC. Since we look for DEC in a patient
population with known clinically proven metastasis, we conclude
that RT–PCR is more sensitive than ICC. Similar results were
found by Zhong et al (1999). Also Slade et al (1999) report a
qualitative correlation between ICC and RT–PCR when these are
applied to the metastatic blood samples. When analysing BM
samples of primary breast cancer patients, a 50% correlation
between the two techniques exists. According to them, we are
working in many cases at the limits of the assays, and therefore
some variation is expected because of sampling errors. In addition,
the samples that were positive by RT–PCR but negative by ICC
may have been so due to the superior sensitivity of PCR.
Schoenfeld et al (1997) found some BM aspirates from breast
cancer patients were RT–PCR failed to detect CK-19 mRNA where
ICC stained some cytokeratin-positive cells. They suggest that
these immunocytochemically detected cells were not viable or that
they were dormant with low metabolic activity as defined by their
inability to synthesise CK-19 mRNA. This highlights the benefit of
using a second test that incorporates morphological assessment of
immunostained cells when interpreting data from RT–PCR
studies. Also, note that Wiedswang et al showed that an increased
rate of detection by ICC does not improve the clinical use of DEC
detection in patients with early breast cancer.
Smith et al found comparable results in blood samples when
analysing both methodologies. They found a significant Spearman
rank correlation when assessing the relationship between RT–PCR
values and numbers of cells detected on ICC . From 133 specimens
analysed and yielding data using both methodologies, 71% showed
the same qualitative results with a moderate k (¼0.43).
In conclusion, while it is unproven that an increased detection
rate would lead to an improved identification of patients at an
increased risk of recurrence, we consider it critical that a
quantitative correlation is demonstrated between ICC and RT–
PCR, enabling the introduction of molecular detection techniques
as part of larger clinical trials.
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